SignalXSignalX

TVRD Tvardi Therapeutics, Inc.

Q3 2025 10-Q
Filed: Nov 13, 2025Period ending Sep 30, 2025
Health Care
Pharmaceutical PreparationsSEC EDGAR
Tvardi Therapeutics, Inc. Overview

Tvardi Therapeutics, Inc. (TVRD) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 13, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Risk Factors

  • • New clinical trial data risk: Phase 2 trial of TTI-101 in IPF failed primary goals as of October 2025, triggering additional analyses and uncertain next steps
  • • Most materially updated financial risk: Cash and equivalents $21.4M, short-term investments $15.0M as of Sept 30, 2025, significant doubt about going concern status
+3 more insights

Quarterly Financial Summary
XBRL

Net Income

-$6M

ROE

-19.8%

Total Assets

$39M

Source: XBRL data from Tvardi Therapeutics, Inc. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Get deeper insights on Tvardi Therapeutics, Inc.

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.